| Document |
Document Title |
|
WO/1996/017823A1 |
Cationic lipids of general formula (I), wherein m is an integer from 2 to 6 inclusive; n is an integer from 1 to 9 inclusive, preferably 1-5, where, when n is 2-9, a single R grouping other than hydrogen is present in the general formula...
|
|
WO/1996/017859A1 |
The invention concerns a process for preparing isoursodesoxycholic acid, wherein the ursodesoxycholic acid is first esterified and the resultant ursodesoxycholic acid ester is reacted by the Mitsunobu reaction to form isoursodesoxycholic...
|
|
WO/1996/016076A1 |
Methods, compositions, and compounds for modulating the GABAA receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.
|
|
WO/1996/013474A1 |
The method described calls for primary and secondary alcohols to be reacted with perfluorobutane sulphonyl fluoride, or with higher homologues such as perfluorooctane sulphonyl fluoride, in the presence of 2-3 equivalents of strong organ...
|
|
WO/1996/012817A1 |
Described is a combination method using selective inhibitors of 5'alpha'-reductase 1 and/or 2 including 7'beta'-substituted 4-aza-5'alpha'-cholestan-3-ones and related 4-aza-5'alpha'-androstan-3-one compounds which are useful in the trea...
|
|
WO/1996/012494A1 |
The present invention concerns the novel use of competitive progesterone antagonists in the preparation of a drug for regulating female fertility as required (pill to be taken as required). This drug can be administered in a single dose ...
|
|
WO/1996/012705A1 |
Compounds of formula (I) wherein: the dotted line indicates that a double bond may be present or absent; R1 is H, methyl or ethyl; R2 is 'alpha'- or 'beta'-C1-10 straight or branched alkyl; R3 is CO2H, CN, CO2R4, COHNR4, or CON(R4)2; R4 ...
|
|
WO/1996/012487A1 |
Described is a combination method using selective inhibitors of 5'alpha'-reductase 1 and/or 2 including 7'beta'-substituted 4-aza-5'alpha'-cholestan-3-ones and related 4-aza-5'alpha'-androstan-3-one compounds which are useful in the trea...
|
|
WO/1996/011206A1 |
The disclosed invention is a process for preparing 17-beta-substituted-androsta-3,5-dien-3-carboxylic acids from 3-halo-17-beta-substituted-androsta-3,5-dienes. The process may be performed in either of two ways: (1) the 3-halo compound ...
|
|
WO/1996/010031A1 |
The invention relates to novel, androstane steroids which are the ligand semiochemicals which bind to neuroepithelial receptors.
|
|
WO/1996/010033A1 |
A process for purifying and preparing phytosterol compositions from pulping soap comprises extracting from the pulping soap a creamy precipitate and purifying this precipitate to form the composition.
|
|
WO/1996/007643A1 |
The novel process of this invention involves the reduction of certain 'DELTA'-5 steroidal alkenes to selectively produce either the 5'alpha' or 5'beta' reduction products. Particularly, this invention involves reduction of 'DELTA'-5 ster...
|
|
WO/1996/004296A1 |
The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human vomeropherin, e.g. a pregnane or cholane steroid, or a pharmaceutical composition containing a vomer...
|
|
WO/1996/003419A1 |
Dammara compounds have immunosuppressant and anti-inflammatory activity and are useful as pharmaceuticals, particularly for use as immunosuppressant and anti-inflammatory agents. 17'alpha' dammara compounds are novel and are included per...
|
|
WO/1996/003420A1 |
The present invention provides a compound of formula (I), wherein A is a bond or a straight or branched C1-C6 alkylene chain; W is a group -R1, -OR2, -NR3R4 or (a) wherein: Y is oxygen or sulphur; R1, R2 and R4 are: a C1-C10 alkyl group,...
|
|
WO/1996/002500A1 |
The invention relates to novel chelate formers containing sulphonamide groups and their metallic chelates of general formula (I) in which n, m, p, V1, V2, V3, V4, X1, X2, X3, R1, R2, R3 and R4 have different meanings, pharmaceutical agen...
|
|
WO/1996/000235A1 |
Certain sterols which can be extracted from bull testes and from human follicular fluid and chemically related sterols can be used for regulating the meiosis in oocytes and in male germ cells.
|
|
WO/1996/000230A1 |
The present invention relates to a process for the preparation and manufacture of 3-amino-substituted glycosylated bile acid derivatives. Novel intermediates and related compounds are also disclosed. In particular, the present invention ...
|
|
WO/1995/032981A1 |
Novel steroidal and non-steroidal enopyranoside compounds, where the enopyranoside is acylated or deacylated, are provided. The steroid and non-steroidal enopyranosides possess the same pharmaceutical properties as their steroid and non-...
|
|
WO/1995/032215A1 |
The instant invention involves a process for oxidizing compounds containing an allylic group, i.e. those containing an allylic hydrogen or allylic alcohol group, to the corresponding enones, using a ruthenium-based catalyst in the presen...
|
|
WO/1995/029186A1 |
The present invention relates to methods and compositions for the transformation of cells. In particular, compositions and methods are disclosed which include combinations of the nucleic acid of interest and polyhydroxylated or polyglyco...
|
|
WO/1995/028413A1 |
Invented are 17'beta'-substituted 3-carboxy steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-'alpha'-reductase.
|
|
WO/1995/024415A1 |
Compounds having a broad range of antimicrobial activity generally have a structure including a steroid nucleus with a cationic, preferably polyamine, side chain (X) and an anionic side chain (Y). The invention is also directed to compou...
|
|
WO/1995/019567A1 |
The invention is directed to synthetic receptor(s) which comprises a polyfunctional organic template covalently linked to two or more oligomers which may independently be the same or different and may independently be straight chain, cyc...
|
|
WO/1995/019186A2 |
Metabolically labile esters, and contrast media for X-ray and magnetic resonance imaging comprising these esters, wherein the esters have formula (I) in which R3 is a steroid residue, the esters containing at least one iodine atom and/or...
|
|
WO/1995/016698A1 |
The present invention is a process for the conversion of bisnoralcohol (I) to bisnoraldehyde (II) which is a known intermediate in the synthesis of progesterone.
|
|
WO/1995/016700A1 |
A process for producing high-quality cholesterol by selectively reducing impurities contained in crude cholesterol, mainly desmosterol, into cholesterol. The process can provide high-purity cholesterol containing at most 0.3 % of desmost...
|
|
WO/1995/016699A1 |
To provide a novel antitumor steroid compound which can be synthesized efficiently and stereoselectively by the technique of organic synthetic chemistry. A steroid derivative represented by general formula (I) or a salt thereof, wherein ...
|
|
WO/1995/015943A1 |
21-norvitamin D3 analogs in which the methyl group normally attached to the side chain at carbon 20 has been replaced by a hydrogen atom. The compounds are characterized by a marked intestinal calcium transport activity while exhibiting ...
|
|
WO/1995/015165A1 |
A method for preventing or reducing restenosis wherein a 27-hydroxycholesterol or a 25,26 and/or 27-aminocholesterol, or a sterol 27-hydroxylase stimulant, is administered in a restenosis preventing and/or reducing amount.
|
|
WO/1995/014662A1 |
Vitamin D2 analogs in which a cyclopentane ring is introduced into the side chain of 1'alpha',25-dihydroxyvitamin D2. The compounds are characterized by a marked intestinal calcium transport activity while exhibiting much lower activity ...
|
|
WO/1995/014032A1 |
A process for producing a 25-hydroxycholesterol by hydroxylating a cholesterol at the 25-position using a ruthenium compound as a catalyst. This process is an industrial process for producing a 25-hydroxylated cholesterol useful as an in...
|
|
WO/1995/008995A1 |
An antiobestic agent containing a 3-ketosteroid compound as the active ingredient and having reduced side effects and toxicity and a high antiobestic activity. The invention also provides a food containing an antiobestic agent containing...
|
|
WO/1995/007919A1 |
The internally cyclized congeners of hydroxy-substituted nucleotide analogues have been found to exhibit substantially lower toxicity in vivo than their uncyclized analogues, while retaining essentially the same antiviral activity. This ...
|
|
WO/1995/007920A1 |
Nucleotide analogs characterized by the presence of an amidate linked amino acid or an ester linked group which is bonded to the phosphorus atom of phosphonate nucleotide analogs are disclosed. The analogs comprise a phosphoamidate or es...
|
|
WO/1995/004535A1 |
The application discloses methods of making medicaments for treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural ...
|
|
WO/1995/001367A1 |
A sterol compound represented by general formula (I), wherein X represents halogen; R1 and R2 represent each independently hydrogen or C2-C5 alkanoyl; and A represents -CO- or -CH(OH)-. The invention provides a novel sterol compound isol...
|
|
WO/1994/026769A1 |
Novel anti-inflammatory compounds, compositions of these compounds and use of such compounds to treat inflammed ocular tissue are described. The compounds are derivatives and analogues of known steroid compounds (e.g., dexamethasone) and...
|
|
WO/1994/025053A1 |
An antigen comprising 5,7 cholestadien-3beta-ol (7-dehydrocholesterol) or a compound having a structure similar to 5,7 cholestadien-3beta-ol and a quaternary ammonium salt is provided. Also provided is a method of generating an antibody ...
|
|
WO/1994/024147A1 |
The compounds of formula (I), wherein R is the residue: (Ia) or (Ib) and the pharmaceutically acceptable salts thereof have therapeutic properties in the treatment of the hepatobiliary pathologies.
|
|
WO/1994/020520A1 |
Compounds having a broad range of antimicrobial activity generally have a structure including a steroid nucleus with a cationic, preferably polyamine, side chain (X) and an anionic side chain (Y). The invention is also directed to compou...
|
|
WO/1994/020519A1 |
Novel compounds having anti-HIV activity are disclosed along with formulations and methods for treating human immunodeficiency viral infections employing these compounds. The figure demonstrates in vitro anti-HIV drug screening results.
|
|
WO/1994/019366A1 |
Methods for the chemical preparation or synthesis of the sterol antibiotic squalamine. Preferably, the preparation is by modifying the 3-position of a 3-oxo-7alpha-hydroxy-24zeta-ether protected alcohol group-5alpha-cholestane with a spe...
|
|
WO/1994/014451A1 |
A composition for the prevention of inflammatory or allergic reaction or the treatment of cardiovascular or haemodynamic disorders comprising a compound of formula (I), where R = (a), and the trans isomer of formula (II), where R = (b), ...
|
|
WO/1994/014433A1 |
Methods of reducing plasma cholesterol levels and treating or preventing atherosclerosis comprising administering an effective amount of a combination of a cholesterol biosynthesis inhibitor and a beta-lactam cholesterol absorption inhib...
|
|
WO/1994/012522A1 |
A process for producing a compound represented by general formula (II) by the reaction of an epoxy compound represented by general formula (I) with an alcohol under a basic condtion, wherein R1 represents hydrogen or a protective group; ...
|
|
WO/1994/011387A2 |
Disclosed is a new process for producing finasteride which involves reacting the magnesium halide salt of 17beta-carboalkoxy-4-aza-5alpha-androst-1-en-3-one with t-butylamino magnesium halide, present in at least a 2:1 molar ratio to the...
|
|
WO/1994/011385A1 |
Invented are novel 17alpha-acyl steroidal 5alpha-reductase inhibiting compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-alpha-reductase. Also invented are novel ...
|
|
WO/1994/011386A1 |
Invented are 17alpha and 17beta-substituted acyl-3-carboxy-3,5-diene analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-alpha-red...
|
|
WO/1994/011004A1 |
Invented are 17alpha and 17beta-substituted acyl-3-carboxy-3,5-diene analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-alpha-red...
|
